Vachon Julien, Campagna Céline, Rodriguez Manuel J, Sirard Marc-André, Levallois Patrick
Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, QC, Canada; Direction de la santé environnementale et de la toxicologie, Institut national de santé publique du Québec (INSPQ), Québec, QC, Canada; Axe Santé des populations et pratiques optimales en santé, Centre de recherche du Centre hospitalier universitaire de Québec, Québec, QC, Canada.
Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, QC, Canada; Direction de la santé environnementale et de la toxicologie, Institut national de santé publique du Québec (INSPQ), Québec, QC, Canada.
Regul Toxicol Pharmacol. 2017 Apr;85:119-123. doi: 10.1016/j.yrtph.2017.01.008. Epub 2017 Jan 27.
Regulatory agencies worldwide need to modernize human health risk assessment (HHRA) to meet challenges of the 21st century. Toxicogenomics is at the core of this improvement. Today, however, the use of toxicogenomics data in HHRA is very limited. The purpose of this survey was to identify barriers to the application of toxicogenomics data in HHRA by human health risk assessors. An online survey targeting Canadian risk assessors gathered information on their knowledge and perception of toxicogenomics, their current and future inclusion of toxicogenomics data in HHRA, and barriers to the use of such data. Twenty-nine (29) participants completed a questionnaire after 2 months of solicitation. The results show that the application of toxicogenomics data in Canada is marginal, with 85% of respondents reporting that they never or rarely used such data. Knowledge of toxicogenomics by Canadian risk assessors is also limited: about two-thirds of respondents (68%) were not at all or only slightly familiar with the concept. Lack of guidelines for toxicogenomics data interpretation, data quality assessment and on their use in HHRA, were found to be major barriers. In conclusion, there is a need for interventions aimed at facilitating the use of toxicogenomics data in HHRA, when available.
全球监管机构需要使人类健康风险评估（HHRA）现代化，以应对21世纪的挑战。毒理基因组学是这一改进的核心。然而如今，毒理基因组学数据在人类健康风险评估中的应用非常有限。本次调查的目的是确定人类健康风险评估人员在将毒理基因组学数据应用于人类健康风险评估时所面临的障碍。一项针对加拿大风险评估人员的在线调查收集了有关他们对毒理基因组学的知识和认知、他们目前及未来在人类健康风险评估中纳入毒理基因组学数据的情况，以及使用此类数据的障碍等信息。在征集2个月后，有29名参与者完成了问卷。结果显示，毒理基因组学数据在加拿大的应用微乎其微，85%的受访者表示他们从未或很少使用此类数据。加拿大风险评估人员对毒理基因组学的了解也很有限：约三分之二的受访者（68%）对这一概念完全不熟悉或只是略有了解。缺乏毒理基因组学数据解读、数据质量评估及其在人类健康风险评估中使用的指南，被认为是主要障碍。总之，有必要采取干预措施，以便在有可用数据时促进毒理基因组学数据在人类健康风险评估中的使用。
